Eli Lilly and Company (NYSE:LLY) Shares Sold by Barrett & Company Inc.

Barrett & Company Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 30.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 736 shares of the company’s stock after selling 316 shares during the period. Barrett & Company Inc.’s holdings in Eli Lilly and Company were worth $652,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. M&G Plc acquired a new position in Eli Lilly and Company during the first quarter worth approximately $8,896,000. Virtu Financial LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $2,138,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Eli Lilly and Company by 19.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares during the period. Mutual Advisors LLC increased its holdings in shares of Eli Lilly and Company by 404.8% during the 1st quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after buying an additional 50,197 shares during the last quarter. Finally, Private Advisor Group LLC raised its position in shares of Eli Lilly and Company by 0.6% in the 1st quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock worth $59,345,000 after buying an additional 430 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $895.71 on Tuesday. The firm has a market cap of $851.29 billion, a price-to-earnings ratio of 131.92, a PEG ratio of 3.24 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The business’s 50 day moving average is $919.22 and its two-hundred day moving average is $864.16. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Analysts forecast that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.58%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. Truist Financial boosted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,013.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.